Needle exchange programs: An economic evaluation of a local experience

CMAJ. Canadian Medical Association Journal

Volumn 157, Issue 3, 1997, Pages 255-262

  Gold, Michelle ^a   Gafni, Amiram ^a   Nelligan, Penny ^b   Millson, Peggy ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b Hamilton Wentworth Reg Pub H   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CANADA; ECONOMIC EVALUATION; HEALTH CARE COST; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; NEEDLE; RESOURCE ALLOCATION;

EID: 0030821006     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Health Canada. Quarterly Surveillance Update: AIDS in Canada. Ottawa: HIV/AIDS Division, Bureau of HIV/AIDS & STD, Laboratory Centre for Disease Control, May 1997.
2. Iannelli M, Loro R, Milner F, Pugliese A, Rabbiolo G. An AIDS model with distributed incubation and variable intectiousness: applications to IV drug users in Latium, Italy. Eur J Epidemiol 1992;8(4):585-93.
3. Des Jarlais DC, Friedman SR. HIV infection and intravenous drug use: critical issues in transmission dynamics, infection outcomes and prevention. Rev Infect Dis 1988;10(1):151-8.
4. Robertson JR, Bucknall ABV, Welsby PD, Roberts JK, Inglis JM, Peutherer JF, Brettle RP. Epidemic of AIDS-related virus (HTLV-III/LAV) infection among intravenous drug abusers. BMJ 1986;292:527-9.
5. Brettle R. HIV and harm reduction for injection drug users. AIDS 1991; 5:125-36.
6. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health 1996;86(5):642-54.
7. Millson P, Coates RA, Rankin J, Myers T, McLaughlin B, Major C, Mindell W. Evaluation of a programme to prevent human immunodeficiency virus transmission in injection drug users in Toronto. Toronto: Department of Preventive Medicine and Biostatistics, University of Toronto; 1992. Final Report of NHDRP grant #6606-4333-AIDS.
8. Baskerville B, Leonard L, Hotz S. Evaluation of the site: a pilot HIV prevention programme for injection drug users. Ottawa: Community Health Research Unit; 1994. CHRU publ no M93-5.
9. Kaplan EH, Heimer R. A circulation theory of needle exchange. AIDS 1994;8:567-74.
10. Des Jarlais DC, Friedman SR, Choopanya K, Vanichseni S, Ward TP. International epidemiology among injecting drug users. AIDS 1992;6:1053-68.
11. Watters J, Estilo M, Clark G, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA 1994;271:115-20.
12. Lurie P, Reingold A, Bowser B. The public health impact of needle exchange programs in the United States and abroad. Vol 1. Prepared for the US Centers for Disease Control and Prevention by the School of Public Health, University of California, Berkeley, and the University of California at San Francisco Institute of Health Policy Studies, San Francisco; 1993.
13. Kall KI, Olin RG. HIV status and changes in risk behaviour among intravenous drug users in Stockholm 1987-1988. AIDS 1990;4:153-7.
14. Ljungberg B, Christensson B, Tunving K, Andersson B, Landvall B, Lundberg M, Zall-Friberg A. HIV prevention among injecting drug users: three years of experience from a syringe exchange program in Sweden. J Acquir Immune Defic Syndr 1991;4(9):890-5.
15. Des Jarlais D, Hagan H, Kriedman SR, Friedmann P, Goldberg D, Frischer M, et al. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA 1995;274:1226-31.
16. Elnitsky SL, Abernathy TJ. Calgary's needle exchange program: profile of injection drug users. Can J Public Health 1993;84(3):177-80.
17. Health Canada. Inventory of HIV incidence/prevalence studies in Canada. Ottawa: Division of HIV/AIDS Epidemiology, Bureau of Communicable Disease Epidemiology, Laboratory Centre for Disease Control; Mar 1995.
18. Hankins C, Gendron S, Rouah F, Godbout C, Mayr I, Lepine D. Rising prevalence? Declining incidence? Montreal's needle exchange: a successful verdict or is the jury still out? [abstract PO-C24-3182]. Int Conf AIDS 1993; 9(2):747.
19. Kaplan EH. Needles that kill: modelling human immunodeficiency virus transmission via shared drug injection equipment in shooting galleries. Rev Infect Dis 1989;11(2):289-96.
20. Nelson KE, Vlahov D, Solomon L, Cohn S, Munoz A. Temporal trends of incident human immunodeficiency virus infection in a cohort of injecting drug users in Baltimore, Md. Arch Intern Med 1995;155:1305-11.
21. Metzger DS, Woody GF, McLellan AT, O'Brien CP, Druley P, Navaline H, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 1993;6(9):1049-56.
22. Kaplan EH, Heimer R. HIV incidence among needle exchange participants: estimates from syringe tracking and testing data. J Acquir Immune Defic Syndr 1994;7(2):182-9.
23. Kaplan EH, Heimer R. HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data. J Acquir Immune Defic Syndr 1995;10(2):175-6.
24. Hurley SF, Kaldor JM, Carlin JB, Gardiner S, Evans DB, Chondros P, et al. The usage and costs of health services for HIV infection in Australia. AIDS 1995;9(7):777-85.
25. Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA 1993; 270:474-8.
26. Rietmeijer CA, Davidson AJ, Foster CT, Cohn DL. Cost of care for patients with human immunodeficiency virus infection: patterns of utilization and charges in a public health care system. Arch Intern Med 1993;153(2):219-25.
27. Alcabes P, Munoz A, Vlahov D, Friedland G. Maturity of human immunodeficiency virus infection and incubation period of acquired immunodeficiency syndrome in injecting drug users. Ann Epidemiol 1994;4(1):17-26.
28. Moore RD, Hidalgo J, Bareta JC, Chaisson RE. Zidovudine therapy and health resource utilization in AIDS. J Acquir Immune Defic Syndr 1994;7(4): 349-54.
29. Grover SA, Gilmore N, Tsoukas C, Falutz J, Sewitch M, Fakhry R. A prospective study of direct health care costs of HIV infected adults in Canada [abstract PO-D28-4226]. Int Conf AIDS 1993;9(2):922.
30. Krahn M, Gafni A. Discounting in the economic evaluation of health care interventions. Med Care 1993;31(5):403-18.
31. DeVillaer M, Smye V. Understanding injection drug users: the first step in planning needle exchange programs. Hamilton (ON): Addiction Research Foundation & Department of Health Services, Regional Municipality of Hamilton-Wentworth; 1994.
32. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford (UK): Oxford Medical Publications; 1987.
33. Hanvelt RA, Ruedy NS, Hogg RS, Strathdee S, Montaner JS, O'Shaughnessy MV, Schechter MT. Indirect costs of HIV/AIDS mortality in Canada. AIDS 1994;8(10):F7-F11.
34. Turner HA, Catania JA, Gagnon J. The prevalence of informal caregiving to persons with AIDS in the United States: caregiver characteristics and their implications. Soc Sci Med 1994;38(11):1543-52.
35. Kaplan EH. Economic analysis of needle exchange. AIDS 1995;9:1113-9.
36. Normand J, Vlahov D, Moses LE, editors. Preventing HIV transmission: the role of sterile needles and bleach. Washington: National Research Council/Institute of Medicine; 1995.
37. Bruneau J, Franco E, Lamothe F, Lachance N, Desy M, Soto J, et al. Increased HIV seroprevalence and seroincidence associated with participation in needle exchange program: unexpected findings from the Saint-Luc cohort study in Montreal [abstract Tu.C.323]. Presented at the XI International Conference on AIDS, Vancouver; 1996.